You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,169,612

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,169,612

Title:	Use of EDG2 receptor in an animal model of heart failure
Abstract:	Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
Inventor(s):	Kostenis; Evi (Grebenau, DE), Wohlfart; Paulus (Bensheim, DE), Huber; Jochen (Maxdorf, DE), Rosport; Kai (Munich, DE), Bueltmann; Andreas (Munich, DE), Baumgartner; Christine (Munich, DE), Muench; Gotz (Munich, DE), Ungerer; Martin (Munich, DE)
Assignee:	Sanofi-Aventis Deutschland GmbH (Frankfurt, DE)
Application Number:	10/706,763
Patent Claims:	1. A myocardial cell of a non-human mammal, wherein the myocardial cell contains an adenoviral vector sequence for simultaneous expression of G protein coupled receptor EDG002 and a cellular marker. 2. The myocardial cell of claim 1, wherein the cellular marker is a fluorescent protein. 3. The myocardial cell of claim 2, wherein the cellular marker is Green Fluorescent Protein. 4. The myocardial cell of claim 2, wherein the adenoviral vector sequence comprises of a recombinant E1/E3 deficient adenovirus which expresses the G protein coupled receptor EDG2 and the fluorescent protein under control of two independent promoters. 5. The myocardial cell of claim 4 wherein the two independent Promoters are two CMV promoters. 6. A method of producing of a myocardial cell according to claim 1, comprising: a. removing the heart of a non-human mammal, b. perfusing the removed heart, digesting the removed heart whit collagenase, and isolating cardiomyocytes, and c infecting the isolated cardiomyocytes with an adenoviral vector comprising a recombinant E1/E3 deficient adenovirus which expresses the G protein coupled receptor EDG2 and a cellular marker under control of two independent promoters. 7. The method of claim 6, wherein the cellular marker is a fluorescent protein.

Details for Patent 7,169,612

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2022-11-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.